Vivani Medical Inc.

$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

IPO Year: 2014

Exchange: NASDAQ

Recent Analyst Ratings for Vivani Medical Inc.

DatePrice TargetRatingAnalyst
See more ratings

Vivani Medical Inc. Press Releases

Fastest customizable press release news feed in the world

See more
  • Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

    Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 Positive NPM-139 (semaglutide implant) preclinical weight loss data comparable to injections of semaglutide, active ingredient in Ozempic®/Wegovy®, with potential for once-yearly dosing Additional $8.25M equity financing which secures solid financial position into the second quarter of 2026, supporting further development of NPM-139 and NPM-115 programs in chronic weight management ALAMEDA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"),

    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Vivani Medical Announces $8.25M Private Placement Equity Financing

    Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it has entered into a securities purchase agreement to issue and sell an aggregate of 7,366,071 shares, each at a price of $1.12 per share, expected to result in gross proceeds of approximately $8.25 million in a p

    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing

    NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development for chronic weight management designed to guarantee medication adherence and potentially improve treatment tolerability by providing smooth and steady delivery of GLP-1 therapy ALAMEDA, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company de

    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

    MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - TodayMarch 26, 2025 11:00Virtual Lobby opens.Register for the Conference.  If you already registered, go back to

    $AEMD
    $ASPI
    $ATCH
    $BNRG
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials
  • Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

    MIAMI, March 25, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com. For updates, follow us on Twitter. Day 1March 26, 2025 11:00Virtual Lobby opens.Register for the Conference. If you already registered, go

    $AEMD
    $ASPI
    $ATCH
    $BNRG
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials
  • Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025

    Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on March 27, 2025. Vivani welcomes individual and institutional investors, along with advisors and analysts, to join its interactive presentation. This live online event will offer existing shareholders and the investment community the opportunity to engage directly with Vivani President and CEO Adam Mendelsohn, Ph.D. Dr. Mendelsohn will provide an overview of the Company and, time permitting, open the floor to questions afterward. Please submit your questions

    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults

    Miniature, twice-yearly GLP-1 (exenatide) implant under development for chronic weight management NPM-115 has demonstrated comparable preclinical weight loss to injections of semaglutide, the active ingredient in Ozempic®/Wegovy® Rapid full study enrollment with all 24 subjects initiating the 8-week run-in period within four weeks; top-line study results expected in mid-2025 Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the successful administration of its first GLP-1 (exenatide) implant in the LIBERATE-1™ clinical trial. This milestone marks a critical step

    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business

    Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent shareholders Cortigent's Orion® artificial vision system, which is in development to treat blindness, completed an initial 6-year clinical study in 2024, with encouraging safety and efficacy results Formerly Second Sight Medical Products, Cortigent achieved the first and only FDA authorization (under a Humanitarian Device Exemption) for an artificial vision device called the Argus® II, which was marketed for a rare form of blindness and implanted in hundreds of patients Cortigent's precision neurostimulation technology is also being developed for the recovery of arm and hand motion in paralysis due to strok

    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

    MIAMI, Jan. 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 78th Emerging Growth Conference on January 15 & 16, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - TodayJanuary 15, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back t

    $BNRG
    $GOVX
    $GRO
    $IPWR
    Building Products
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Presenting on the Emerging Growth Conference 78 Day 1 on January 15 Register Now

    MIAMI, Jan. 14, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 78th Emerging Growth Conference on January 15 & 16, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1January 15, 2025 9:00Virtual Lobby opens.Register for the Conference.  If you already registered, go back to the r

    $BNRG
    $GOVX
    $GRO
    $IPWR
    Building Products
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

Vivani Medical Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

Vivani Medical Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

Vivani Medical Inc. SEC Filings

See more

Vivani Medical Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more